Takeshita, Yumie
Nomura, Chiaki
Murai, Hisayoshi
Mukai, Yusuke
Hirai, Tadayuki
Hamaoka, Takuto
Tokuno, Shota
Tanaka, Takeo
Goto, Hisanori
Nakano, Yujiro
Usui, Soichiro
Nakajima, Kenichi
Takamura, Masayuki
Takamura, Toshinari http://orcid.org/0000-0002-4393-3244
Funding for this research was provided by:
Japan Association for Diabetes Education and Care (2022-FND-014)
Article History
Received: 23 August 2023
Accepted: 12 October 2023
First Online: 26 October 2023
Declarations
:
: Yumie Takeshita and Toshinari Takamura have received consulting fees from Kowa Company Ltd. and Sumitomo Pharma Receipt of grants or research support: Yumie Takeshita has received lecture fees from Sumitomo Pharma, Kowa Company Ltd., and Sanofi. Toshinari Takamura has received lecture fees from MSD, Sumitomo Dainippon Pharma, Kowa Company Ltd., and Mitsubishi Tanabe Pharma Corp. Toshinari Takamura has received research grants from Taisyo PharmaCo., Kowa Company Ltd., Life Scan Japan, Sanwa Kagaku Kenkyusho Co. Ltd., SumitomoPharma, Kowa Company Ltd., Mitsubishi Tanabe Pharma Corp., Abbott, and Nippon Boehringer Ingelheim Co., Ltd. Chiaki Nomura, Hisayoshi Murai, Yusuke Mukai, Tadayuki Hirai, Takuto Hamaoka, Shota Tokuno, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Soichiro Usui, Kenichi Nakajima, and Masayuki Takamura have nothing to disclose.
: The institutional review board of each participating institution has approved the study protocol in compliance with the Declaration of Helsinki and current legal regulations in Japan. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients that are willing to participate in the study.